Harrow Inc
HROW41.300USD
+0.280+0.68%
Close 11/26, 16:00（ET）Quotes delayed by 15 min
1.53BMarket Cap
LossP/E TTM
More Details of Harrow Inc Company
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Harrow Inc Info
Ticker SymbolHROW
Company nameHarrow Inc
IPO dateFeb 08, 2013
CEOMr. John P. Saharek
Number of employees382
Security typeOrdinary Share
Fiscal year-endFeb 08
Address1A Burton Hills Blvd
CityNASHVILLE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code37215
Phone16157334731
Websitehttps://www.harrow.com/
Ticker SymbolHROW
IPO dateFeb 08, 2013
CEOMr. John P. Saharek
Company Executives of Harrow Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Randall E. Pollard, CPA
Mr. Randall E. Pollard, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Product Sales Net
63.66M
0.00%
Transfer of acquired product sales/profit
85.00K
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product Sales Net
63.66M
0.00%
Transfer of acquired product sales/profit
85.00K
0.00%
Shareholding Stats
Updated: Tue, Nov 25
Updated: Tue, Nov 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
10.54%
Baum (Mark L)
7.79%
BlackRock Institutional Trust Company, N.A.
6.02%
The Vanguard Group, Inc.
5.03%
Private Capital Management
5.01%
Other
65.61%
Shareholders
Shareholders
Proportion
Opaleye Management Inc.
10.54%
Baum (Mark L)
7.79%
BlackRock Institutional Trust Company, N.A.
6.02%
The Vanguard Group, Inc.
5.03%
Private Capital Management
5.01%
Other
65.61%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.52%
Investment Advisor/Hedge Fund
19.69%
Individual Investor
15.70%
Hedge Fund
14.61%
Research Firm
2.10%
Pension Fund
0.83%
Bank and Trust
0.36%
Insurance Company
0.03%
Private Equity
0.02%
Other
26.13%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
360
21.75M
58.77%
-3.27M
2025Q2
345
26.63M
72.57%
-2.99M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
2023Q2
265
25.64M
85.30%
+312.85K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Opaleye Management Inc.
3.90M
10.55%
-35.00K
-0.89%
Jun 30, 2025
Baum (Mark L)
2.89M
7.8%
+286.66K
+11.03%
Jul 21, 2025
BlackRock Institutional Trust Company, N.A.
2.25M
6.09%
-21.27K
-0.94%
Jun 30, 2025
The Vanguard Group, Inc.
1.86M
5.03%
+3.81K
+0.21%
Jun 30, 2025
Private Capital Management
1.95M
5.26%
+54.73K
+2.90%
Jun 30, 2025
Kaufman (Daniel)
1.68M
4.55%
-222.91K
-11.69%
Aug 12, 2024
State Street Investment Management (US)
773.11K
2.09%
-13.38K
-1.70%
Jun 30, 2025
Boll (Andrew R)
777.84K
2.1%
+209.75K
+36.92%
Apr 21, 2025
Geode Capital Management, L.L.C.
810.80K
2.19%
+36.72K
+4.74%
Jun 30, 2025
Royce Investment Partners
553.69K
1.5%
+226.60K
+69.28%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
SPDR S&P Pharmaceuticals ETF
2.45%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.84%
Invesco Dorsey Wright Healthcare Momentum ETF
0.94%
First Trust Small Cap Growth AlphaDEX Fund
0.79%
iShares U.S. Pharmaceuticals ETF
0.59%
Invesco Dorsey Wright SmallCap Momentum ETF
0.47%
First Trust Small Cap Core Alphadex Fund
0.36%
iShares Micro-Cap ETF
0.32%
ProShares Ultra Nasdaq Biotechnology
0.18%
Invesco Nasdaq Biotechnology ETF
0.18%
View more
SPDR S&P Pharmaceuticals ETF
Proportion2.45%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.84%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.94%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.79%
iShares U.S. Pharmaceuticals ETF
Proportion0.59%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.47%
First Trust Small Cap Core Alphadex Fund
Proportion0.36%
iShares Micro-Cap ETF
Proportion0.32%
ProShares Ultra Nasdaq Biotechnology
Proportion0.18%
Invesco Nasdaq Biotechnology ETF
Proportion0.18%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Harrow Inc?
The top five shareholders of Harrow Inc are:
Opaleye Management Inc. holds 3.90M shares, accounting for 10.55% of the total shares.
Baum (Mark L) holds 2.89M shares, accounting for 7.80% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.25M shares, accounting for 6.09% of the total shares.
The Vanguard Group, Inc. holds 1.86M shares, accounting for 5.03% of the total shares.
Private Capital Management holds 1.95M shares, accounting for 5.26% of the total shares.
Opaleye Management Inc. holds 3.90M shares, accounting for 10.55% of the total shares.
Baum (Mark L) holds 2.89M shares, accounting for 7.80% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.25M shares, accounting for 6.09% of the total shares.
The Vanguard Group, Inc. holds 1.86M shares, accounting for 5.03% of the total shares.
Private Capital Management holds 1.95M shares, accounting for 5.26% of the total shares.
What are the top three shareholder types of Harrow Inc?
The top three shareholder types of Harrow Inc are:
Opaleye Management Inc.
Baum (Mark L)
BlackRock Institutional Trust Company, N.A.
Opaleye Management Inc.
Baum (Mark L)
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Harrow Inc (HROW)?
As of 2025Q3, 360 institutions hold shares of Harrow Inc, with a combined market value of approximately 21.75M, accounting for 58.77% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -13.80%.
What is the biggest source of revenue for Harrow Inc?
In FY2025Q2, the Product Sales Net business generated the highest revenue for Harrow Inc, amounting to 63.66M and accounting for --% of total revenue.
